Literature DB >> 7357870

STS 557, a new orally active progestin with antiprogestational and contragestational properties in rabbits.

M Oettel, A Kurischko.   

Abstract

STS 557 (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4.9(10)-diene-3-one) is a potent progestin. This compound was 10 times as potent as the standard levonorgestrel as judged by the classic Clauberg-McPhail Assay. The antiprogestational response is significant when STS 557 treatment starts 2 days before progesterone administration. It does not disturb the priming activity of estradiol. This compound alone is adequate for endometrial priming. Early pregnancy is maintained in ovariectomized does. Administration on day 1 of pregnancy reduces the number of implantations. In comparison with chlormadinone acetate and d-norgestrel, only STS 557 treatment causes complete inhibition of egg fertilization.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7357870     DOI: 10.1016/0010-7824(80)90140-7

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  4 in total

1.  Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys.

Authors:  S Sasagawa; Y Shimizu; T Nagaoka; H Tokado; K Imada; K Mizuguchi
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

Review 2.  Dienogest.

Authors:  R H Foster; M I Wilde
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

Review 3.  Estradiol valerate/dienogest.

Authors:  Keri Wellington; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Product-to-parent reversion of trenbolone: unrecognized risks for endocrine disruption.

Authors:  Shen Qu; Edward P Kolodziej; Sarah A Long; James B Gloer; Eric V Patterson; Jonas Baltrusaitis; Gerrad D Jones; Peter V Benchetler; Emily A Cole; Kaitlin C Kimbrough; Matthew D Tarnoff; David M Cwiertny
Journal:  Science       Date:  2013-09-26       Impact factor: 47.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.